Who is sponsoring NCT06350617?

NCT06350617 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT06350617?

Interventions in NCT06350617: High-Frequency, ipsilateral M1, High-Frequency, bilateral M1, High-Frequency, Lt. DLPFC, High-Frequency, bilateral M1.

What condition does NCT06350617 study?

NCT06350617 studies Parkinson's Disease and Parkinsonism.

Is NCT06350617 still recruiting?

NCT06350617 is currently recruiting now. Last updated 5 April 2024.

Last reviewed 2024-04-05 · How we verify

NCT06350617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients

Recruiting now NA Last updated 5 April 2024

What this trial tests

NA trial testing High-Frequency, ipsilateral M1 in Parkinson's Disease and Parkinsonism in 60 participants. Currently enrolling.

Timeline

20 February 2024

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	Samsung Medical Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	20 February 2024
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across South Korea

Drugs / interventions tested

High-Frequency, ipsilateral M1
High-Frequency, bilateral M1
High-Frequency, Lt. DLPFC
High-Frequency, bilateral M1

Conditions studied

Parkinson's Disease and Parkinsonism — all drugs for Parkinson's Disease and Parkinsonism →

Sponsor

Samsung Medical Center

Who can join

50 and older, any sex, with Parkinson's Disease and Parkinsonism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of personalized repetitive transcranial magnetic stimulation based on functional reserve to enhance ambulatory function in patients with Parkinson's disease: study protocol for a randomized controlled trial.
Yun SJ, Lee HS, Kim DH, Im S, et al · · 2024 · cited 3× · PMID 39152467 · DOI 10.1186/s13063-024-08385-2

Verify or expand the search:

Other recruiting trials for Parkinson's Disease and Parkinsonism

Currently open trials in the same condition.

NCT07153692 — Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD · NA · recruiting
NCT06914466 — Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD · recruiting
NCT06400017 — Mechanism and Application of DBS in the Treatment of PD · NA · recruiting
NCT06174948 — The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders · NA · recruiting
NCT05934747 — Aim 3 Particle Swarm Optimization PIGD · NA · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06350617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 5 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06350617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing